Isn’t it time you start seeing better?

Dr. K. Bailey Freund is moderating and speaking at the Midwest Ocular Angiography Conference in Kona, Hawaii this week. He will be speaking on optical coherence tomography revealing tangled vascular networks in eyes with neovascular age-related macular degeneration showing resistance to geographic atrophy and multimodal imaging of the pachychoroid spectrum.

Dr. Yale Fisher is speaking this week at the 30th meeting of the Club Jules Gonin in Bordeaux, France.  Dr. Fisher is speaking on ophthalmic ultrasonography, including different ways of imaging asteroid hyalosis, vitreous hemorrhage, retinal detachment, complications due to diabetic retinopathy, and visualization of the retina through dense cataracts.

Dr. Richard Spaide lectured at the Yale Ophthalmology Spring Symposium/Alumni Day 2016.  He spoke on Vascular Abnormalization with Periodic Antiangiogenic Therapy in Age-Related Macular Degeneration. Over the 45 year history of the Department of Ophthalmology and Visual Science at Yale, scientific discovery and treatment options for the range of ocular diseases have evolved into a massive body of knowledge. The faculty presenters at this symposium are contemporary experts in focused ophthalmic disciplines including cornea and external disease, glaucoma and retina, and will describe vision-saving medical and surgical therapies now considered the gold standard. This year's symposium explored updates in pediatric ophthalmology and adult retinal disorders, in addition to comprehensive offerings in glaucoma, cornea, and visual science. For more information about this symposium, click here.

Richard F. Spaide, MD was the recipient of the 2016 Roger H. Johnson Award, which is given every two years by the University of Washington.  The selection committee accepts nominations of clinicians and scientists throughout the world for this highly esteemed recognition.  According to the committee, "The successful candidate will be the nominee who is deemed by the selection committee to have made the most significant contribution to our understand of the pathogenesis or treatment of AMD."  

Dr. Michael Engelbert was featured on the Review of Ophthalmology en español cover for his work on the understanding of vitreous structure.  To read the entire publication, click here.

VRMNY is recruiting patients for the BOULEVARD study, a Phase II clinical trial for newly diagnosed diabetic macular edema (DME). Patients will be randomized to receive standard anti-VEGF Lucentis injections or a new drug that combines anti-VEGF and anti-Ang2. Ang2 is another factor that promotes new abnormal blood vessel formation. This 7-month study will help determine if this new combination drug better preserves the vision of patients with DME. Treatments will be provided free of charge. For more information or to see if you qualify for the study, contact our research department at research@vrmny.com or (212) 452-6965.  You may also visit the BOULEVARD Clinical Trials website.